Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Christian Josef Wiedermann
 -- 1332 2022-05-17 07:58:55 |
2 layout
Camila Xu
 + 3 word(s) 1335 2022-05-17 08:09:51 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Wiedermann, C. Hyperoncotic Human Albumin Solution in Traumatic Brain Injury. Encyclopedia. Available online: https://encyclopedia.pub/entry/22993 (accessed on 16 April 2024).
Wiedermann C. Hyperoncotic Human Albumin Solution in Traumatic Brain Injury. Encyclopedia. Available at: https://encyclopedia.pub/entry/22993. Accessed April 16, 2024.
Wiedermann, Christian. "Hyperoncotic Human Albumin Solution in Traumatic Brain Injury" Encyclopedia, https://encyclopedia.pub/entry/22993 (accessed April 16, 2024).
Wiedermann, C. (2022, May 17). Hyperoncotic Human Albumin Solution in Traumatic Brain Injury. In Encyclopedia. https://encyclopedia.pub/entry/22993
Wiedermann, Christian. "Hyperoncotic Human Albumin Solution in Traumatic Brain Injury." Encyclopedia. Web. 17 May, 2022.
Hyperoncotic Human Albumin Solution in Traumatic Brain Injury
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11092662

Fluid resuscitation with human albumin solution (HAS) corrects low serum albumin levels and aids in preserving euvolemia in non-brain-injured intensive care units and in perioperative patients. Ischemia, hypotension, hypoxia, and energy dysfunction are important determinants of the outcomes following a severe traumatic brain injury (TBI). Cerebral edema and increased intracranial pressure (ICP) are frequently observed after TBI, leading to cerebral ischemia.

albumin brain injury intracranial pressure

1. Introduction

Despite continuous advances in intensive care, the mortality and permanent disability rates after head injuries remain high [1][2]. Ischemia, hypotension, hypoxia, and energy dysfunction are important determinants of the outcomes following a severe traumatic brain injury (TBI). Cerebral edema and increased intracranial pressure (ICP) are frequently observed after TBI, leading to cerebral ischemia. A complex series of pathological events triggers the propagation of this secondary injury cascade to cerebral areas that are initially not involved in TBI [3]. The mortality among patients with TBI is significantly increased in the presence of intracranial hypertension (ICP ≥ 20 mmHg), regardless of the cerebral perfusion pressure (CPP) [4], and patient management has focused on preventing or ameliorating the secondary injury that occurs in the ensuing hours and days following the primary initial trauma. An overarching goal of medical management is to ensure optimal cerebral perfusion and oxygenation [5].
Intravenous fluids play a central role in the management of TBI, allowing adequate CPP to be maintained and helping to avoid intracerebral edema and elevated ICP. However, fluids can have both favorable and unfavorable consequences because of the potential risks of hyperhydration and hypo- or hyperosmolar conditions, which may affect the clinical course and outcome of TBI [6].

2. Use of Human Albumin Solutions in Fluid Management of Traumatic Brain Injury (TBI)

Recent evidence of the low risk of bias confirmed that the use of 20–25% (hyperoncotic) human albumin solution (HAS) to correct low serum albumin levels aids in preserving euvolemia in non-brain-injured intensive care units and perioperative patients [7][8]. Previously, an infusion of 25% HAS was shown to prevent intracerebral edema in patients with TBI [9] and decrease ICP after craniotomy [10].
An ICP-targeted treatment concept for TBI was developed by investigators in Lund, Sweden, utilizing hyperoncotic HAS to maintain euvolemia and colloid osmotic pressure [11]. However, HAS as a replacement fluid in acute brain injury patients is not used in most centers worldwide and is not recommended in international clinical guidelines because of reports of adverse outcomes of HAS infusion [12][13][14]. Specifically, the SAFE-TBI study (a post-hoc follow-up analysis of 290 patients from the randomized SAFE trial) reported higher mortality in those receiving 4% HAS [15]. The researchers of this post-hoc analysis suggested that increased albumin may have crossed the damaged blood–brain barrier into the brain tissue, resulting in a greater net outflow of fluid from the cerebral intravascular space into the interstitial brain tissue. An increase in cerebral edema, increase in cerebral pressure, more frequent use of cerebral pressure-lowering measures and, finally, increased mortality in the 4% HAS group compared to the group receiving physiological saline for volume therapy were observed [15][16].
These findings remain the subject of debate, because the patients were not enrolled in the SAFE study according to any specific set of TBI-related criteria, and the use of a hypotonic preparation of 4% HAS, particularly in conjunction with the liberal use of vasopressors and relatively high hydrostatic pressure, may have been suboptimal for the patients with severe TBI [17]. The mean change in ICP from randomization to 14 days post-randomization was subsequently analyzed in a post-hoc subgroup of 209 patients of the 290 patient SAFE-TBI study subgroup associated with the use of 4% HAS with increased ICP on day 7 but not on day 3, day 14, or overall [18]. In this subgroup analysis of a subgroup, the initial mean ICP was 21% higher in the group allocated to 4% HAS (p = 0.06), and no attempt was made to adjust for this imbalance [18]. Experimental findings directly comparing the commercially available hypotonic 4% HAS used in the SAFE study (4% Albumex (278 mOsm/kg)) with a novel isotonic 4% HAS (288 mOsm/kg) finally confirmed that the tonicity of 4% HAS, rather than the albumin itself, was responsible for increasing the ICP [19].
A recently published BaSICS study in Brazil confirmed this hypothesis [20]. When comparing a balanced infusion solution (Plasma-Lyte 148®, Baxter Hospitalar, Brazil) to isotonic saline, a subgroup analysis of the patients with TBI showed that a significantly higher 90-day survival rate was observed under isotonic saline than in patients treated with the balanced solution [21]. Compared to the 0.9% saline solution, the balanced solution used had a theoretical osmolarity of 296 vs. 308 mOsmol/L, whereas the measured osmolality showed an osmolar difference of 271 vs. 296 mOsmol/kgH2O [22].
The European Society of Intensive Care Medicine (ESICM) consensus and clinical practice recommendations suggest against the use of 4% or 20% HAS as the resuscitation fluid in acute brain injury patients with low blood pressure independent of HAS tonicity (weak recommendation) [14], despite the existence of suggestive evidence that the Lund concept of normalization of plasma oncotic pressure with slowly infused 20–25% HAS may lower the mortality rate compared with alternative approaches in TBI. Several studies have consistently reported low mortality rates ranging from 8% to 20% in patients with severe TBI [23][24][25][26][27][28][29][30][31][32][33], whereas the mean percentages of all injury-related mortality caused by or associated with TBI in Europe and the United States are 37% and 30.5%, respectively [34].

3. Mechanistic Considerations for the Use of Hyperoncotic HAS in TBI

The physiological considerations of intravenous HAS as a replacement fluid and the extant clinical evidence for and against its use within the various facets of modern neuroanesthesia and neurocritical care practice were recently explored and reviewed by Ma and Bebawy [13]. The recommendation was made so that, in the absence of definitive data to either support or dissuade from the use of HAS in most neurosurgical scenarios, practitioners should consider the potential risks and benefits of HAS administration. In the narrative research, no mention was made of the ICP-targeted treatment of TBI utilizing 20–25% HAS [13], suggesting that data on HAS administration in the context of the Lund concept have not been taken into consideration.
HAS infusion to maintain normal serum albumin levels is the cornerstone of the Lund concept [11][12]. HAS is an effective volume expander and, along with erythrocyte transfusions, aids in preserving euvolemia, reducing reliance on vasopressors, and thereby averting intracranial hypertension. Additionally, as the chief endogenous colloid of human plasma, albumin sustains oncotic forces that retain the fluid in the intravascular compartment, consequently minimizing tissue edema in the injured brain and the rest of the body. The administration of concentrated albumin prevented or reduced cerebral edema in two randomized trials [9][35] and in a nonrandomized controlled study [36].
Research has identified a wide range of putative roles for HAS in modifying inflammation, maintaining vascular endothelial integrity and the acid–base balance, and ligating endogenous and exogenous compounds [37], which may all play important roles in the pathophysiology of severe TBI. Albumin can offer protection from inflammatory processes and the associated damage to the microcirculation and tissues, with an impact on the outcome [38].
In addition, supporting the utility of HAS is the observation that hypoalbuminemia is independently associated with increased mortality among severe TBI patients [39]. The kinetics of albumin involves a transcapillary leak and breakdown, leading to hypoalbuminemia, which is associated with the worse outcomes in a broad spectrum of conditions [40]. The correction of hypoalbuminemia with hyperoncotic HAS infusion can be beneficial, as it improves the hemodynamic stability in patients with sepsis [41] and prevents acute kidney injury in cardiac surgery patients [42]. Intravenous hyperoncotic HAS has been determined to be safe for use as resuscitation fluid in most critically ill patients [7].
Neuroinflammation is recognized as an interaction between central and peripheral components that is influenced by age, sex, type of TBI and its severity, and other factors, including the timing of the diagnostic and therapeutic interventions that may have a significant impact on the outcome [43]. Although HAS therapy in TBI may have neuroprotective potential [44], no data supporting this hypothesis are currently available. Moreover, the colloids used in the Lund concept were not restricted to hyperoncotic 20% HAS but also included 4% HAS, plasma, and packed red blood cells (no synthetic colloids were used) [45]. If the timing of 20% HAS administration, i.e., early vs. late in TBI, is important remains speculative.

References

  1. Patel, H.C.; Bouamra, O.; Woodford, M.; King, A.T.; Yates, D.W.; Lecky, F.E. Trends in Head Injury Outcome from 1989 to 2003 and the Effect of Neurosurgical Care: An Observational Study. Lancet 2005, 366, 1538–1544.
  2. Beck, B.; Gantner, D.; Cameron, P.A.; Braaf, S.; Saxena, M.; Cooper, D.J.; Gabbe, B.J. Temporal Trends in Functional Outcomes after Severe Traumatic Brain Injury: 2006–2015. J. Neurotrauma 2018, 35, 1021–1029.
  3. Kinoshita, K. Traumatic Brain Injury: Pathophysiology for Neurocritical Care. J. Intensive Care 2016, 4, 29.
  4. Juul, N.; Morris, G.F.; Marshall, S.B.; Marshall, L.F. Intracranial Hypertension and Cerebral Perfusion Pressure: Influence on Neurological Deterioration and Outcome in Severe Head Injury. The Executive Committee of the International Selfotel Trial. J. Neurosurg. 2000, 92, 1–6.
  5. Stocchetti, N.; Carbonara, M.; Citerio, G.; Ercole, A.; Skrifvars, M.B.; Smielewski, P.; Zoerle, T.; Menon, D.K. Severe Traumatic Brain Injury: Targeted Management in the Intensive Care Unit. Lancet Neurol. 2017, 16, 452–464.
  6. Rossi, S.; Picetti, E.; Zoerle, T.; Carbonara, M.; Zanier, E.R.; Stocchetti, N. Fluid Management in Acute Brain Injury. Curr. Neurol. Neurosci. Rep. 2018, 18, 74.
  7. Wiedermann, C.J. Phases of Fluid Management and the Roles of Human Albumin Solution in Perioperative and Critically Ill Patients. Curr. Med. Res. Opin. 2020, 36, 1961–1973.
  8. Haynes, G. Growing Evidence for Hyperoncotic 20% Albumin Solution for Volume Resuscitation. J. Cardiothorac. Vasc. Anesth. 2020, 34, 1702–1703.
  9. Tomita, H.; Ito, U.; Tone, O.; Masaoka, H.; Tominaga, B. High Colloid Oncotic Therapy for Contusional Brain Edema. Acta Neurochirurgica Suppl. 1994, 60, 547–549.
  10. Miyasaka, Y.; Nakayama, K.; Matsumori, K.; Beppu, T.; Tanabe, T.; Kitahara, T.; Saito, T. Albumin therapy for patients with increased intracranial pressure: Oncotic therapy. No Shinkei Geka 1983, 11, 947–954.
  11. Grände, P.-O. The “Lund Concept” for the Treatment of Severe Head Trauma—Physiological Principles and Clinical Application. Intensive Care Med. 2006, 32, 1475–1484.
  12. Grände, P.-O.; Juul, N. Guidelines for Treatment of Patients with Severe Traumatic Brain Injury. In Management of Severe Traumatic Brain Injury; Springer: Berlin/Heidelberg, Germany, 2020; pp. 395–401.
  13. Ma, H.K.; Bebawy, J.F. Albumin Use in Brain-Injured and Neurosurgical Patients: Concepts, Indications, and Controversies. J. Neurosurg. Anesthesiol. 2021, 33, 293–299.
  14. Oddo, M.; Poole, D.; Helbok, R.; Meyfroidt, G.; Stocchetti, N.; Bouzat, P.; Cecconi, M.; Geeraerts, T.; Martin-Loeches, I.; Quintard, H.; et al. Fluid Therapy in Neurointensive Care Patients: ESICM Consensus and Clinical Practice Recommendations. Intensive Care Med. 2018, 44, 449–463.
  15. SAFE Study Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australian Red Cross Blood Service; George Institute for International Health; Myburgh, J.; Cooper, D.J.; Finfer, S.; Bellomo, R.; Norton, R.; Bishop, N.; et al. Saline or Albumin for Fluid Resuscitation in Patients with Traumatic Brain Injury. N. Engl. J. Med. 2007, 357, 874–884.
  16. Gantner, D.; Moore, E.M.; Cooper, D.J. Intravenous Fluids in Traumatic Brain Injury: What’s the Solution? Curr. Opin. Crit. Care 2014, 20, 385–389.
  17. Drummond, J.C.; Patel, P.M.; Lemkuil, B. Proscribing the Use of Albumin in the Head-Injured Patient Is Not Warranted. Anesth. Analg. 2011, 113, 426–427, author reply 427–428.
  18. Cooper, D.J.; Myburgh, J.; Heritier, S.; Finfer, S.; Bellomo, R.; Billot, L.; Murray, L.; Vallance, S.; SAFE-TBI Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Albumin Resuscitation for Traumatic Brain Injury: Is Intracranial Hypertension the Cause of Increased Mortality? J. Neurotrauma 2013, 30, 512–518.
  19. Iguchi, N.; Kosaka, J.; Bertolini, J.; May, C.N.; Lankadeva, Y.R.; Bellomo, R. Differential Effects of Isotonic and Hypotonic 4% Albumin Solution on Intracranial Pressure and Renal Perfusion and Function. Crit. Care Resusc. J. Australas. Acad. Crit. Care Med. 2018, 20, 48–53.
  20. Briegel, J. Albumin in traumatic brain injury-osmolarity is what matters! Med. Klin. Intensivmed. und Notf. 2022, 117, 69–70.
  21. Zampieri, F.G.; Machado, F.R.; Biondi, R.S.; Freitas, F.G.R.; Veiga, V.C.; Figueiredo, R.C.; Lovato, W.J.; Amêndola, C.P.; Serpa-Neto, A.; Paranhos, J.L.R.; et al. Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial. JAMA 2021, 326, 818–829.
  22. Weinberg, L.; Collins, N.; Van Mourik, K.; Tan, C.; Bellomo, R. Plasma-Lyte 148: A Clinical Review. World J. Crit. Care Med. 2016, 5, 235–250.
  23. Asgeirsson, B.; Grände, P.O.; Nordström, C.H. A New Therapy of Post-Trauma Brain Oedema Based on Haemodynamic Principles for Brain Volume Regulation. Intensive Care Med. 1994, 20, 260–267.
  24. Eker, C.; Asgeirsson, B.; Grände, P.O.; Schalén, W.; Nordström, C.H. Improved Outcome after Severe Head Injury with a New Therapy Based on Principles for Brain Volume Regulation and Preserved Microcirculation. Crit. Care Med. 1998, 26, 1881–1886.
  25. Naredi, S.; Edén, E.; Zäll, S.; Stephensen, H.; Rydenhag, B. A Standardized Neurosurgical Neurointensive Therapy Directed toward Vasogenic Edema after Severe Traumatic Brain Injury: Clinical Results. Intensive Care Med. 1998, 24, 446–451.
  26. Naredi, S.; Olivecrona, M.; Lindgren, C.; Ostlund, A.L.; Grände, P.O.; Koskinen, L.O. An Outcome Study of Severe Traumatic Head Injury Using the “Lund Therapy” with Low-Dose Prostacyclin. Acta Anaesthesiol. Scand. 2001, 45, 402–406.
  27. Wahlström, M.R.; Olivecrona, M.; Koskinen, L.-O.D.; Rydenhag, B.; Naredi, S. Severe Traumatic Brain Injury in Pediatric Patients: Treatment and Outcome Using an Intracranial Pressure Targeted Therapy—The Lund Concept. Intensive Care Med. 2005, 31, 832–839.
  28. Olivecrona, M.; Rodling-Wahlström, M.; Naredi, S.; Koskinen, L.-O.D. Effective ICP Reduction by Decompressive Craniectomy in Patients with Severe Traumatic Brain Injury Treated by an ICP-Targeted Therapy. J. Neurotrauma 2007, 24, 927–935.
  29. Olivecrona, M.; Rodling-Wahlström, M.; Naredi, S.; Koskinen, L.-O.D. Prostacyclin Treatment in Severe Traumatic Brain Injury: A Microdialysis and Outcome Study. J. Neurotrauma 2009, 26, 1251–1262.
  30. Olivecrona, M.; Rodling-Wahlström, M.; Naredi, S.; Koskinen, L.-O.D. Prostacyclin Treatment and Clinical Outcome in Severe Traumatic Brain Injury Patients Managed with an ICP-Targeted Therapy: A Prospective Study. Brain Inj. 2012, 26, 67–75.
  31. Gautschi, O.P.; Huser, M.C.; Smoll, N.R.; Maedler, S.; Bednarz, S.; von Hessling, A.; Lussmann, R.; Hildebrandt, G.; Seule, M.A. Long-Term Neurological and Neuropsychological Outcome in Patients with Severe Traumatic Brain Injury. Clin. Neurol. Neurosurg. 2013, 115, 2482–2488.
  32. Stenberg, M.; Koskinen, L.-O.; Levi, R.; Stålnacke, B.-M. Severe Traumatic Brain Injuries in Northern Sweden: A Prospective 2-Year Study. J. Rehabil. Med. 2013, 45, 792–800.
  33. Koskinen, L.-O.D.; Olivecrona, M.; Grände, P.O. Severe Traumatic Brain Injury Management and Clinical Outcome Using the Lund Concept. Neuroscience 2014, 283, 245–255.
  34. Maas, A.I.R.; Menon, D.K.; Adelson, P.D.; Andelic, N.; Bell, M.J.; Belli, A.; Bragge, P.; Brazinova, A.; Büki, A.; Chesnut, R.M.; et al. Traumatic Brain Injury: Integrated Approaches to Improve Prevention, Clinical Care, and Research. Lancet Neurol. 2017, 16, 987–1048.
  35. Gürkan, F.; Haspolat, K.; Yaramiş, A.; Ece, A. Beneficial Effect of Human Albumin on Neonatal Cerebral Edema. Am. J. Ther. 2001, 8, 253–254.
  36. Tone, O.; Ito, U.; Tomita, H.; Masaoka, H.; Tominaga, B. High Colloid Oncotic Therapy for Brain Edema with Cerebral Hemorrhage. Acta Neurochir. Suppl. 1994, 60, 568–570.
  37. Ferrer, R.; Mateu, X.; Maseda, E.; Yebenes, J.C.; Aldecoa, C.; De Haro, C.; Ruiz-Rodriguez, J.C.; Garnacho-Montero, J. Non-Oncotic Properties of Albumin. A Multidisciplinary Vision about the Implications for Critically Ill Patients. Expert Rev. Clin. Pharmacol. 2018, 11, 125–137.
  38. Hariri, G.; Joffre, J.; Deryckere, S.; Bige, N.; Dumas, G.; Baudel, J.L.; Maury, E.; Guidet, B.; Ait-Oufella, H. Albumin Infusion Improves Endothelial Function in Septic Shock Patients: A Pilot Study. Intensive Care Med. 2018, 44, 669–671.
  39. Yang, T.-J.; Fei, M.-M.; Ye, W.; Pan, A.-J.; Liu, B. Effect of albumin and hemoglobin level on prognosis of patients with uncomplicated severe traumatic brain injury: A retrospective cohort study. Chin. Crit. Care Med. 2013, 25, 301–305.
  40. Soeters, P.B.; Wolfe, R.R.; Shenkin, A. Hypoalbuminemia: Pathogenesis and Clinical Significance. J. Parenter. Enter. Nutr. 2019, 43, 181–193.
  41. Caironi, P.; Tognoni, G.; Masson, S.; Fumagalli, R.; Pesenti, A.; Romero, M.; Fanizza, C.; Caspani, L.; Faenza, S.; Grasselli, G.; et al. Albumin Replacement in Patients with Severe Sepsis or Septic Shock. N. Engl. J. Med. 2014, 370, 1412–1421.
  42. Lee, E.H.; Kim, W.J.; Kim, J.Y.; Chin, J.H.; Choi, D.K.; Sim, J.Y.; Choo, S.J.; Chung, C.H.; Lee, J.W.; Choi, I.C. Effect of Exogenous Albumin on the Incidence of Postoperative Acute Kidney Injury in Patients Undergoing Off-Pump Coronary Artery Bypass Surgery with a Preoperative Albumin Level of Less than 4.0 g/dL. Anesthesiology 2016, 124, 1001–1011.
  43. Marklund, N. Pharmacological Neuroprotection. In Management of Severe Traumatic Brain Injury: Evidence, Tricks, and Pitfalls; Sundstrøm, T., Grände, P.-O., Luoto, T., Rosenlund, C., Undén, J., Wester, K.G., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 409–419. ISBN 978-3-030-39383-0.
  44. Khatri, R.; Afzal, M.R.; Rodriguez, G.J.; Maud, A.; Miran, M.S.; Qureshi, M.A.; Cruz-Flores, S.; Qureshi, A.I. Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter? Neurocrit. Care 2018, 28, 60–64.
  45. Rodling Wahlström, M.; Olivecrona, M.; Nyström, F.; Koskinen, L.-O.D.; Naredi, S. Fluid Therapy and the Use of Albumin in the Treatment of Severe Traumatic Brain Injury. Acta Anaesthesiol. Scand. 2009, 53, 18–25.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Critical Care Medicine
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Christian Wiedermann
View Times: 757
Revisions: 2 times (View History)
Update Date: 17 May 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback